Table 1. Baseline characteristics (n = 161).
| Variables | Values |
| Demographic variables | |
| Age (years) | 49 (18–81) |
| Male gender | 102 (63.4) |
| Body mass index (kg/m2) | 24.4 (14.3–34.3) |
| Diabetes mellitus | 28 (17.4) |
| Etiology, NAFLD/HBV/HCV/Others | 72 (44.7)/49 (30.4)/28 (17.4)/12 (7.5) |
| Biochemical parameters | |
| Aspartate aminotransferase (IU/L) | 45.2±36.2 |
| Alanine aminotransferase (IU/L) | 49.8±43.8 |
| Serum albumin (g/dL) | 4.1±0.5 |
| Fasting glucose (mg/mL) | 109.6±35.2 |
| Total cholesterol (mg/mL) | 172.2±40.5 |
| Triglycerides (mg/mL) | 128.5±60.3 |
| Liver biopsy | |
| Fibrosis stage | |
| F0–1/F2/F3/F4 | 65 (40.4)/44 (27.3)/22 (13.7)/30 (18.6) |
| Activity grade | |
| A0/A1/A2/A3 | 23 (14.3)/27 (16.8)/74 (46.0)/37 (23.0) |
| Steatosis | |
| S0/S1/S2/S3 | 42 (26.1)/80 (49.7)/33 (20.5)/6 (3.7) |
| Biopsy length (cm) | 18.5 (16.1–24.2) |
| Liver stiffness measurement | |
| Liver stiffness value (kPa) | 8.1 (2.9–75.0) |
| Interquartile range (kPa) | 1.0 (0.1–14.0) |
| IQR/M | 0.12 (0.01∼0.35) |
| Controlled attenuation parameter | |
| Controlled attenuation parameter value (dB/m) | 255 (149–400) |
| Interquartile range (dB/m) | 29.0 (6–76) |
| IQR/MCAP | 0.12 (0.02–0.33) |
Variables are expressed as median (range) or n (%). NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B; HCV, hepatitis C; kPa, kilopascal; IQR/M, interquartile range/median liver stiffness value; CAP, controlled attenuation parameter; IQR/MCAP, interquartile range/median of CAP value.